University of Pennsylvania

Halda Therapeutics appoints Christian Schade as CEO, aiming to advance RIPTAC™ therapeutics for cancer treatment.

Precision Neuroscience's Layer 7 Cortical Interface enables unprecedented brain signal mapping, decoding movement and speech with high accuracy, advancing brain-computer interface technology.

Naveris presents NavDx® test data at 2024 ASTRO, highlighting its role in managing HPV-driven oropharyngeal cancers, with studies showing its effectiveness in predicting treatment outcomes and guiding therapy adjustments.

The fifth Precision Medicine Conference at the University of Granada highlighted advances in innovative technologies for personalized treatment, with sessions on AI, nanotechnology, and various diseases. The event showcased the ibs.GRANADA's role in precision medicine research.

Cabaletta Bio (CABA) pioneers CD19 auto-CAR-T therapies for immunology diseases, facing volatility and challenges in manufacturing and patient enrollment. Despite hurdles, CABA's first-mover advantage in CAR-T for immunology could lead to durable drug-free remissions, potentially transforming treatment standards.

Alexander Fanaroff, MD, MHS, Assistant Professor of Medicine at the University of Pennsylvania, presents 'Rigorous Testing of Behavior Change Interventions: Lessons from the BE ACTIVE Randomized Clinical Trial' on Oct 18, 2024, 1-2 p.m. ET. Join via Zoom link with passcode 796831.

Jennifer Egan, Pulitzer Prize-winning author, speaks Oct. 30 at FAU’s MacArthur Campus as part of the Starry Nights series. The event, presented by the Wilkes Honors College and Osher Lifelong Learning Institute, includes public talks and interactive sessions with students. Egan’s visit marks the college’s 25th anniversary, with additional events featuring Ryan Serhant and Jeanette Walls.

Gene therapy trials for hereditary blindness show significant improvement in night vision for patients with Leber congenital amaurosis 1 (LCA1) and RLBP-1 associated retinal dystrophy, with plans for future Phase III trials.

Gene therapy Beqvez (fidanacogene elaparvovec) significantly reduces bleeding episodes in hemophilia B patients by 71% after a single infusion, with over half experiencing no bleeds, according to a clinical trial published in the New England Journal of Medicine. The therapy, approved by the FDA in April 2024, uses a virus to deliver a working factor IX gene to the liver, enabling continuous production of the clotting factor. Patients report a 'hemophilia-free state of mind' post-treatment.

Beqvez gene therapy significantly reduces bleeding episodes in hemophilia B patients, with 71% average drop and 50% bleed-free outcomes post-infusion, per NEJM study. FDA approved in April 2024, offering a single-dose alternative to regular factor IX infusions.